(R)-2-(benzyloxy)-5-(3-methylmorpholino)-N-(pyridazin-4-yl)benzamide

ID: ALA4436378

Chembl Id: CHEMBL4436378

PubChem CID: 155511739

Max Phase: Preclinical

Molecular Formula: C23H24N4O3

Molecular Weight: 404.47

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  C[C@@H]1COCCN1c1ccc(OCc2ccccc2)c(C(=O)Nc2ccnnc2)c1

Standard InChI:  InChI=1S/C23H24N4O3/c1-17-15-29-12-11-27(17)20-7-8-22(30-16-18-5-3-2-4-6-18)21(13-20)23(28)26-19-9-10-24-25-14-19/h2-10,13-14,17H,11-12,15-16H2,1H3,(H,24,26,28)/t17-/m1/s1

Standard InChI Key:  RMQJXUQZNIBWQJ-QGZVFWFLSA-N

Alternative Forms

1. Parent:

   

   ALA4436378

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 404.47

Molecular Weight (Monoisotopic): 404.1848

AlogP: 3.53

#Rotatable Bonds: 6

Polar Surface Area: 76.58

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.77

CX Basic pKa: 2.75

CX LogP: 2.74

CX LogD: 2.74

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.68

Np Likeness Score: -1.41

References

1. Ding X, Stasi LP, Dai X, Long K, Peng C, Zhao B, Wang H, Sun C, Hu H, Wan Z, Jandu KS, Philps OJ, Chen Y, Wang L, Liu Q, Edge C, Li Y, Dong K, Guan X, Tattersall FD, Reith AD, Ren F..  (2019)  5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.,  29  (2): [PMID:30522952] [10.1016/j.bmcl.2018.11.054]

Source

Source(1):

• Scientific Literature